-
Immuno Oncology: If cancer was a pathogen, would a vaccine be able to destroy it?(Post)
Thanks to the great intuitions of brilliant scientists like Louis Pasteur, Edward Jenner, Robert Koch, Emil von Behring, Gaston Leon Ramon, Albert Sabin, Jonas Salk in the past century, the
Western Blot Sample Protocol - Mandarin(Page)蛋白质印迹样本方案(Western Blot,中文) | Assay Genie
MHC Class I vs Class II: Key Differences & Functions [Guide](Post)Immunology Guide MHC Class I vs Class II: Key Differences & Functions [Guide] Major Histocompatibility Complex molecules present antigens to T
Mechanisms of HIV persistence during HAART(Post)HIV Virus: Replication Cycle and Pathogenesis in absence of HAART The human immunodeficiency virus (HIV) is a formidable pathogen that has posed a significant global
A Quick Guide to Myelin(Post)Neuroscience · Myelin BiologyA Quick Guide to MyelinMyelin is the lipid-rich insulating sheath wrapped around nerve axons. Made by oligodendrocytes in the central nervous system and Schwann cells in t
CD86: Enhancing T Cell Activation in Immunotherapy(Post)Introduction to CD86 and Its Role in Immune Activation CD86 is a crucial co-stimulatory molecule that plays an essential role in T cell activation, driving the immune system’s ability to
B-Cell Depletion: Why Anti-CD20 Spares the Antibody(Post)You can remove almost every B cell from an animal and barely move its antibody titre. That is not a failed experiment — it is the expected result, and it follows from one fact: CD20 is switched off a
4 étapes pour des comptes rendus ELISA défendables en laboratoire(Post)Un compte rendu ELISA exploitable réunit l’objectif de l’essai, la référence et le lot du kit, la méthode suivie, les densités optiques brutes, le modèle d’ajustement retenu (4PL ou 5PL) et les fa
Utomilumab: Advancing Immuno-Oncology Research(Post)Quick Facts About UtomilumabWhat is Utomilumab?Utomilumab is a monoclonal antibody targeting 4-1BB (CD137), a co-stimulatory receptor on T-cells, designed to enhance anti-tumor immunity.
Transformation Protocol – Sample Transformation Protocols(Post)Introduction Transformation of bacteria with plasmids is not only of note for bacterial studies but also can be used for gene expression studies in mammalian cells. Most plasmids are of bact
Rescuing Exhausted T Cells: A New Frontier in Cancer Immunotherapy(Post)For decades, the fight against cancer has been a story of incremental gains. But what if we could fundamentally shift the battlefield, turning the body's own immune system into a precision-guided weap
How we can target the underlying immune processes in pathological inflammation in obesity, cancer and liver disease.(Post)Dr. Melissa Conroy, TTMI I am an immunologist and senior research fellow in the Cancer Immunology and Immunotherapy Group, Department of Surgery at Trinity
Gemtuzumab: Advancing CD33-Targeted Therapies in AML Research(Post)Key Facts About GemtuzumabWhat is Gemtuzumab?Gemtuzumab is an antibody-drug conjugate (ADC) targeting CD33, a protein expressed on the surface of myeloid cells. It is widely recognized f
Autophagy alterations in Alzheimer’s disease(Post)By Diana-Madalina Stan, PhD student, University of Salford Disease Description Alzheimer’s disease (AD), the most common cause of dementia, is a neu
BTLA: A Key Player in Immune Regulation and Cancer Therapy(Post)Introduction to BTLA in Immune Regulation B and T lymphocyte attenuator (BTLA) is an immune checkpoint molecule that plays a critical role in regulating immune responses by suppressing T
Beyond Burnout: How T Cell Exhaustion Hijacks Cancer Immunity and What We Can Do About It(Post)Imagine a highly trained soldier, elite and effective, sent to the front lines of a relentless war. Day after day, they fight without rest, their supplies dwindle, and the enemy never stops coming. Ev
Everything You Need to Know About Preeclampsia: A Guide(Post)Preeclampsia is a serious condition that can develop during pregnancy. It is marked by high blood pressure and the presence of protein in the urine and can cause serious problems for b
Vopratelimab: Unlocking the Potential of ICOS in Cancer Research(Post)What You Need to Know About VopratelimabWhat is Vopratelimab?Vopratelimab is an experimental monoclonal antibody that targets the Inducible T-cell CO-Stimulator (ICOS) protein, playing a
Labetuzumab: Revolutionizing Cancer Research with Targeted Therapies(Post)Quick Facts About LabetuzumabWhat is Labetuzumab?Labetuzumab is a monoclonal antibody targeting CEACAM5, a protein overexpressed in various cancers, primarily colorectal carcinoma.How do
Indusatumab: Advancing Anti-CD47 Cancer Research with Biosimilar Innovations(Post)Quick Facts About IndusatumabWhat is Indusatumab?Indusatumab is an experimental antibody therapy targeting CD47, a protein that enables cancer cells to evade immune destruction.How does